Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CNS Pharmaceuticals, Inc.CNSP · Entity 8048 | Director · Chief Executive Officer | November 17, 2025 | November 19, 2025 |
| Moleculin Biotech, Inc.MBRX · Entity 7886 | Director | November 12, 2025 | November 14, 2025 |
| STAR EQUITY HOLDINGS, INC.DRAD · Entity 76212 | Director | August 16, 2019 | August 19, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CNS Pharmaceuticals, Inc.
Report date November 17, 2025 · Filed November 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $30.00 · Expires 2035-11-17 | Direct | 9,761 |
Reported balance
After 2025-11-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-17 · Grant · Acquired 9,761 · Balance 9,761 F1: The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on March 11, 2025 (the "Grant Date"), subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025. F3: Issued in connection with the reporting person's employment with the Company. F2: The options set forth in the table vest as follows: 50% on the six-month anniversary of the Grant Date, 25% on the 12-month anniversary of the Grant Date, and 25% on the 18-month anniversary of the Grant Date, subject to the reporting person's continued employment on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on March 11, 2025 (the "Grant Date"), subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025.
F2: The options set forth in the table vest as follows: 50% on the six-month anniversary of the Grant Date, 25% on the 12-month anniversary of the Grant Date, and 25% on the 18-month anniversary of the Grant Date, subject to the reporting person's continued employment on each vesting date.
F3: Issued in connection with the reporting person's employment with the Company.
Moleculin Biotech, Inc.
Report date November 12, 2025 · Filed November 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.49 · Expires 2035-11-12 | Direct | 165,169 |
Reported balance
After 2025-11-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-12 · Grant · Acquired 150,000 · Balance 165,169 F2: The options were issued in connection with the reporting person's Board of Director service to the Company. F1: The options set forth in this table vest on November 12, 2026, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options set forth in this table vest on November 12, 2026, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.
F2: The options were issued in connection with the reporting person's Board of Director service to the Company.
STAR EQUITY HOLDINGS, INC.
Report date August 16, 2019 · Filed August 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 2,250 |
Reported balance
After 2019-08-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-08-16 · Grant · Acquired 2,250 · Balance 2,250 F1: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F2: One hundred percent (100%) of the Restricted Stock Units are scheduled to vest on the one (1) year anniversary of August 16, 2019, subject to the Reporting Person continuing to be a service provider through such date. |
| Common StockSEC Table I · non-derivative | Direct | 6,910 |
Reported balance
Holding disclosure · report date 2019-08-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 6,910 |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock.
F2: One hundred percent (100%) of the Restricted Stock Units are scheduled to vest on the one (1) year anniversary of August 16, 2019, subject to the Reporting Person continuing to be a service provider through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIRNER DENTAL MANAGEMENT SERVICES INC
Report date January 14, 2019 · Filed January 14, 2019
Section 16 reporting ended · disclosed 2019-01-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-01-14 transaction · row 1
1 source rowRow 1 · 2019-01-14 · Disposition to issuer · Disposed 4,000 · Balance 0 F1: Disposed of as a result of a merger pursuant to the previously announced Agreement and Plan of Merger, dated as of October 3, 2018 (the "Merger Agreement"), by and among the issuer, Mid-Atlantic Dental Services Holdings, LLC, and Bronco Acquisition, Inc., in exchange for, on a per share basis, (i) $10.62 in cash and (ii) a contingent value right entitling the holder thereof to receive up to $0.13 per share that may become payable after 18 months in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of as a result of a merger pursuant to the previously announced Agreement and Plan of Merger, dated as of October 3, 2018 (the "Merger Agreement"), by and among the issuer, Mid-Atlantic Dental Services Holdings, LLC, and Bronco Acquisition, Inc., in exchange for, on a per share basis, (i) $10.62 in cash and (ii) a contingent value right entitling the holder thereof to receive up to $0.13 per share that may become payable after 18 months in accordance with the terms of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 17, 2025 Filed Nov 19, 2025 17:00 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 9,761 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001683168-25-008564 · ownership.xml · derivative · entry 1 Climaco John M · CIK 0001546797 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,761 Underlying: Common Stock · 9,761 shares Expires 2035-11-17 F1 · date: The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on March 11, 2025 (the "Grant Date"), subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025. F3 · price: Issued in connection with the reporting person's employment with the Company. F2 · derivative.exercise_date: The options set forth in the table vest as follows: 50% on the six-month anniversary of the Grant Date, 25% on the 12-month anniversary of the Grant Date, and 25% on the 18-month anniversary of the Grant Date, subject to the reporting person's continued employment on each vesting date. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:05 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock Options (right to buy) · Derivative | 150,000 | Not disclosed Strike: $0.49 | Not disclosed |
DisclosureSEC source: 0001437749-25-035170 · rdgdoc.xml · derivative · entry 1 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,169 Underlying: Common Stock · 150,000 shares Expires 2035-11-12 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest on November 12, 2026, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| November 04, 2024 Filed Nov 7, 2024 01:04 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001437749-24-033708 · rdgdoc.xml · derivative · entry 1 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,169 Underlying: Common Stock · 10,000 shares Expires 2034-11-04 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest through April 2025, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 21:50 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantRestricted Stock Units · Derivative | 83,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-24-002284 · ownership.xml · derivative · entry 2 Climaco John M · CIK 0001546797 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 559,533 Underlying: Common Stock · 83,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Company common stock. F2 · price: Issued in connection with the reporting person's employment with the Company. F4 · derivative.exercise_date: The restricted stock units set forth in the table vest in eight equal quarterly installments over two years. F4 · derivative.expiration_date: The restricted stock units set forth in the table vest in eight equal quarterly installments over two years. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 21:50 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 83,000 | Not disclosed Strike: $0.26 | Not disclosed |
DisclosureSEC source: 0001683168-24-002284 · ownership.xml · derivative · entry 1 Climaco John M · CIK 0001546797 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 476,533 Underlying: Common Stock · 83,000 shares Expires 2034-04-08 F2 · price: Issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: The options set forth in the table vest in 36 equal monthly installments over three years. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 10:27 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantSeries B Warrant to purchase common stock · Derivative | 166,666 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001683168-24-000705 · ownership.xml · derivative · entry 3 Climaco John M · CIK 0001546797 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 393,533 Underlying: Common Stock · 166,666 shares Expires 2025-10-01 F1 · price: The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 10:27 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantSeries A Warrant to purchase common stock · Derivative | 166,666 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001683168-24-000705 · ownership.xml · derivative · entry 2 Climaco John M · CIK 0001546797 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,867 Underlying: Common Stock · 166,666 shares Expires 2029-02-01 F1 · price: The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 10:27 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | PurchaseCommon stock | 166,666 | $0.30 | $49,999.80 |
DisclosureSEC source: 0001683168-24-000705 · ownership.xml · nonDerivative · entry 1 Climaco John M · CIK 0001546797 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,676 F1 · price: The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024. Read SEC document |
| August 16, 2023 Filed Aug 16, 2023 16:01 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | PurchaseCommon Stock | 2,750 | $1.80 | $4,944.50 |
DisclosureSEC source: 0001683168-23-005828 · ownership.xml · nonDerivative · entry 1 Climaco John M · CIK 0001546797 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,010 Read SEC document |
| May 25, 2023 Filed May 26, 2023 21:16 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001437749-23-016002 · rdgdoc.xml · derivative · entry 1 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,501 Underlying: Common Stock · 15,000 shares Expires 2033-05-25 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest on the earlier of one year from the date of the Company's 2023 annual meeting of stockholders or on the next annual meeting of stockholders, subject to the grantee's continued service on the Company's Board of Directors on such vesting date. Read SEC document |
| April 28, 2023 Filed May 1, 2023 18:59 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-23-002830 · ownership.xml · derivative · entry 2 Climaco John M · CIK 0001546797 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,201 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · price: On April 28, 2022, the reporting person received 20,000 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors. F2 · derivative.exercise_date: On April 28, 2022, the reporting person received 20,000 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors. F2 · derivative.expiration_date: On April 28, 2022, the reporting person received 20,000 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors. Read SEC document |
| April 28, 2023 Filed May 1, 2023 18:59 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-23-002830 · ownership.xml · nonDerivative · entry 1 Climaco John M · CIK 0001546797 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 16:20 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | PurchaseCommon Stock | 15,000 | $0.69 | $10,408.50 |
DisclosureSEC source: 0001683168-23-002405 · ownership.xml · nonDerivative · entry 1 Climaco John M · CIK 0001546797 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,010 F1 · price: This transaction was executed in multiple trades at prices ranging from $0.677 to $0.70. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 19:28 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantRestricted Stock Units · Derivative | 16,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-23-002096 · ownership.xml · derivative · entry 1 Climaco John M · CIK 0001546797 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,451 Underlying: Common stock · 16,467 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of Issuer common stock. F3 · price: Issued in connection with the reporting person's employment with the Company. F2 · derivative.exercise_date: The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 50% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $6.00 (subject to pro rata adjustment for stock splits or similar events); and (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $24.00 (subject to pro rata adjustment for stock splits or similar events). F2 · derivative.expiration_date: The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 50% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $6.00 (subject to pro rata adjustment for stock splits or similar events); and (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $24.00 (subject to pro rata adjustment for stock splits or similar events). Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 23:04 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $1.49 | Not disclosed |
DisclosureSEC source: 0001437749-22-015662 · rdgdoc.xml · derivative · entry 2 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,501 Underlying: Common Stock · 15,000 shares Expires 2032-06-20 F3 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F2 · derivative.exercise_date: The options set forth in this table vest on the earlier of one year from the date of the Company's 2022 annual meeting of stockholders or on the date of the next annual meeting of stockholders, subject the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 23:04 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 23,333 | Not disclosed Strike: $1.49 | Not disclosed |
DisclosureSEC source: 0001437749-22-015662 · rdgdoc.xml · derivative · entry 1 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,501 Underlying: Common Stock · 23,333 shares Expires 2032-06-20 F3 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest in three equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| April 28, 2022 Filed Apr 29, 2022 17:11 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantRestricted Stock Units · Derivative | 600,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-22-003053 · ownership.xml · derivative · entry 1 Climaco John M · CIK 0001546797 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,349,500 Underlying: Common Stock · 600,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of Issuer common stock. F3 · price: Issued in connection with the reporting person's employment with the Company. F2 · derivative.exercise_date: The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors. F2 · derivative.expiration_date: The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 08:30 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantCommon Stock | 35,000 | $0.28 | $9,835.00 |
DisclosureSEC source: 0001683168-22-001495 · ownership.xml · nonDerivative · entry 1 Climaco John M · CIK 0001546797 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 940,298 Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 20:07 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantCommon Stock | 5,000 | $1.28 | $6,400.00 |
DisclosureSEC source: 0001683168-21-005823 · ownership.xml · nonDerivative · entry 1 Climaco John M · CIK 0001546797 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 905,298 Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:25 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $3.95 | Not disclosed |
DisclosureSEC source: 0001437749-21-014427 · rdgdoc.xml · derivative · entry 1 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,168 Underlying: Common Stock · 10,000 shares Expires 2031-06-07 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest in four quarterly installments, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 17:00 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock (right to buy) · Derivative | 310,000 | Not disclosed Strike: $3.36 | Not disclosed |
DisclosureSEC source: 0001683168-21-000447 · ownership.xml · derivative · entry 1 Climaco John M · CIK 0001546797 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 749,500 Underlying: Common Stock · 310,000 shares Expires 2031-02-05 F2 · price: The stock options were issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest in four equal annual installments beginning on the first anniversary of the Transaction Date and are subject to the grantee's continued service to the Company on each vesting date. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:32 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $1.12 | Not disclosed |
DisclosureSEC source: 0001659617-20-000152 · wf-form4_159242592252592.xml · derivative · entry 1 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-15 F2 · price: (2) Issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: (1) The options set forth in this table vest in four quarterly installments, subject to the grantee's continued service on the Company's Board of Directors in each vesting date. Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 16:19 UTC | STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 | GrantRestricted Stock Unit · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-19-002281 · form409271cli_08192019.xml · derivative · entry 2 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 2,250 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: One hundred percent (100%) of the Restricted Stock Units are scheduled to vest on the one (1) year anniversary of August 16, 2019, subject to the Reporting Person continuing to be a service provider through such date. F2 · derivative.expiration_date: One hundred percent (100%) of the Restricted Stock Units are scheduled to vest on the one (1) year anniversary of August 16, 2019, subject to the Reporting Person continuing to be a service provider through such date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 16:41 UTC | STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 | Exercise / conversionRestricted Stock Unit · Derivative | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-19-002143 · form40927cli_08082019.xml · derivative · entry 2 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F3 · derivative.exercise_price: This transaction represents the settlement of Restricted Stock Units in shares of common stock on their scheduled vesting date. F1 · shares: On June 4, 2019, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F4 · derivative.exercise_date: On August 6, 2018 the Reporting Person was granted 12,500 Restricted Stock Units (prior to the Reverse Stock Split). As to this grant, 100% of the Restricted Stock Units fully vested on August 6, 2019. F4 · derivative.expiration_date: On August 6, 2018 the Reporting Person was granted 12,500 Restricted Stock Units (prior to the Reverse Stock Split). As to this grant, 100% of the Restricted Stock Units fully vested on August 6, 2019. F1 · derivative.underlying_shares: On June 4, 2019, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 16:41 UTC | STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 | Exercise / conversionCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-19-002143 · form40927cli_08082019.xml · nonDerivative · entry 1 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On June 4, 2019, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F3 · price: This transaction represents the settlement of Restricted Stock Units in shares of common stock on their scheduled vesting date. F1 · balance_after: On June 4, 2019, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 20:14 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $1.31 | Not disclosed |
DisclosureSEC source: 0001659617-19-000103 · wf-form4_156322163353261.xml · derivative · entry 1 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 35,000 shares Expires 2029-07-11 F2 · price: (2) The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: (1) The options set forth in this table vest in four quarterly installments, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| May 22, 2019 Filed May 24, 2019 21:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $1.15 | Not disclosed |
DisclosureSEC source: 0001144204-19-028197 · tv522433_4.xml · derivative · entry 1 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 15,000 shares Expires 2029-05-22 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest in four quarterly installments, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 20:26 UTC | STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 | PurchaseCommon Stock | 6,000 | $0.82 | $4,920.00 |
DisclosureSEC source: 0000921895-19-000806 · form409271001cli_03182019.xml · nonDerivative · entry 1 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,600 Read SEC document |
| January 14, 2019 Filed Jan 14, 2019 16:52 UTC | BIRNER DENTAL MANAGEMENT SERVICES INC BDMS · Entity 161087 | Disposition to issuerCommon Stock | 4,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-19-000996 · form4.xml · nonDerivative · entry 1 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of as a result of a merger pursuant to the previously announced Agreement and Plan of Merger, dated as of October 3, 2018 (the "Merger Agreement"), by and among the issuer, Mid-Atlantic Dental Services Holdings, LLC, and Bronco Acquisition, Inc., in exchange for, on a per share basis, (i) $10.62 in cash and (ii) a contingent value right entitling the holder thereof to receive up to $0.13 per share that may become payable after 18 months in accordance with the terms of the Merger Agreement. F1 · price: Disposed of as a result of a merger pursuant to the previously announced Agreement and Plan of Merger, dated as of October 3, 2018 (the "Merger Agreement"), by and among the issuer, Mid-Atlantic Dental Services Holdings, LLC, and Bronco Acquisition, Inc., in exchange for, on a per share basis, (i) $10.62 in cash and (ii) a contingent value right entitling the holder thereof to receive up to $0.13 per share that may become payable after 18 months in accordance with the terms of the Merger Agreement. Read SEC document |
| August 08, 2018 Filed Aug 8, 2018 19:33 UTC | STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 | Exercise / conversionRestricted Stock Unit · Derivative | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-18-002228 · form4cli09271004_08082018.xml · derivative · entry 3 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_price: This transaction represents the settlement of Restricted Stock Units in shares of common stock on their scheduled vesting date. F1 · price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F4 · derivative.exercise_date: On August 8, 2017 the Reporting Person was granted 12,500 Restricted Stock Units. As to this grant, 100% of the Restricted Stock Units fully vested on August 8, 2018. F4 · derivative.expiration_date: On August 8, 2017 the Reporting Person was granted 12,500 Restricted Stock Units. As to this grant, 100% of the Restricted Stock Units fully vested on August 8, 2018. Read SEC document |
| August 08, 2018 Filed Aug 8, 2018 19:33 UTC | STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-18-002228 · form4cli09271004_08082018.xml · nonDerivative · entry 1 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F2 · price: This transaction represents the settlement of Restricted Stock Units in shares of common stock on their scheduled vesting date. Read SEC document |
| August 06, 2018 Filed Aug 8, 2018 19:33 UTC | STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 | GrantRestricted Stock Unit · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-18-002228 · form4cli09271004_08082018.xml · derivative · entry 2 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F3 · derivative.exercise_date: One hundred percent (100%) of the Restricted Stock Units are scheduled to vest on the one (1) year anniversary of August 6, 2018, subject to the Reporting Person continuing to be a service provider through such date. F3 · derivative.expiration_date: One hundred percent (100%) of the Restricted Stock Units are scheduled to vest on the one (1) year anniversary of August 6, 2018, subject to the Reporting Person continuing to be a service provider through such date. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 13:46 UTC | BIRNER DENTAL MANAGEMENT SERVICES INC BDMS · Entity 161087 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003078 · primarydocument.xml · nonDerivative · entry 1 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F1 · shares: Restricted stock that vests in two equal installments on June 20, 2019 and June 20, 2020 Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:27 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $1.82 | Not disclosed |
DisclosureSEC source: 0001144204-18-033609 · tv496093_4.xml · derivative · entry 1 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 35,000 shares Expires 2028-06-06 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest in three equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service on the Companya(euro)(TM)s Board of Directors on each vesting date. Read SEC document |
| August 08, 2017 Filed Aug 10, 2017 17:11 UTC | STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 | GrantRestricted Stock Unit · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-17-002087 · form409271cli_08102017.xml · derivative · entry 1 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: One hundred percent (100%) of the Restricted Stock Units are scheduled to vest on the one (1) year anniversary of August 8, 2017, subject to the Reporting Person continuing to be a service provider through such date. F2 · derivative.expiration_date: One hundred percent (100%) of the Restricted Stock Units are scheduled to vest on the one (1) year anniversary of August 8, 2017, subject to the Reporting Person continuing to be a service provider through such date. Read SEC document |
| August 02, 2017 Filed Aug 4, 2017 18:15 UTC | STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 | Exercise / conversionRestricted Stock Unit · Derivative | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193805-17-001417 · form409271cli_08042017.xml · derivative · entry 2 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_price: This transaction represents the settlement of Restricted Stock Units in shares of common stock on their scheduled vesting date. F1 · price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F3 · derivative.exercise_date: On August 2, 2016 the Reporting Person was granted 12,500 Restricted Stock Units. As to this grant, 100% of the Restricted Stock Units fully vested on August 2, 2017. F3 · derivative.expiration_date: On August 2, 2016 the Reporting Person was granted 12,500 Restricted Stock Units. As to this grant, 100% of the Restricted Stock Units fully vested on August 2, 2017. Read SEC document |
| August 02, 2017 Filed Aug 4, 2017 18:15 UTC | STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193805-17-001417 · form409271cli_08042017.xml · nonDerivative · entry 1 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F2 · price: This transaction represents the settlement of Restricted Stock Units in shares of common stock on their scheduled vesting date. Read SEC document |
| July 24, 2017 Filed Jul 27, 2017 01:06 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantOption to purchase common stock · Derivative | 20,000 | Not disclosed Strike: $1.87 | Not disclosed |
DisclosureSEC source: 0001144204-17-038495 · v471461_4.xml · derivative · entry 1 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-07-24 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest in three equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 09:46 UTC | BIRNER DENTAL MANAGEMENT SERVICES INC BDMS · Entity 161087 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-021927 · form4.xml · nonDerivative · entry 1 Climaco John M · CIK 0001546797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · shares: Restricted stock that vests in two equal installments on June 20, 2018 and June 20, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.